Amedisys Inc (NASDAQ:AMED) – Oppenheimer issued their Q1 2019 EPS estimates for Amedisys in a research note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn expects that the health services provider will post earnings of $0.63 per share for the quarter. Oppenheimer also issued estimates for Amedisys’ Q2 2019 earnings at $0.71 EPS, Q3 2019 earnings at $0.71 EPS, Q4 2019 earnings at $0.74 EPS and FY2019 earnings at $2.79 EPS.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Amedisys from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Royal Bank of Canada restated a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. Mizuho restated a “buy” rating and issued a $65.00 target price (up from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. William Blair restated an “outperform” rating on shares of Amedisys in a report on Tuesday, November 21st. Finally, SunTrust Banks restated a “buy” rating and issued a $70.00 target price on shares of Amedisys in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) traded down $1.29 during midday trading on Wednesday, hitting $55.74. 408,825 shares of the stock were exchanged, compared to its average volume of 380,800. The stock has a market capitalization of $1,858.37, a P/E ratio of 44.59, a PEG ratio of 1.17 and a beta of 0.71. Amedisys has a 1-year low of $43.48 and a 1-year high of $65.91. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 earnings per share.

A number of institutional investors have recently added to or reduced their stakes in AMED. Riverhead Capital Management LLC grew its holdings in Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after purchasing an additional 831 shares during the period. Federated Investors Inc. PA lifted its position in Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in Amedisys during the third quarter valued at approximately $205,000. Amalgamated Bank acquired a new position in Amedisys during the second quarter valued at approximately $246,000. Finally, NorthCoast Asset Management LLC acquired a new position in Amedisys during the third quarter valued at approximately $262,000. Hedge funds and other institutional investors own 94.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Q1 2019 Earnings Forecast for Amedisys Inc (AMED) Issued By Oppenheimer” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/17/q1-2019-earnings-forecast-for-amedisys-inc-amed-issued-by-oppenheimer.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.